prikaz prve stranice dokumenta Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
  Download
PDF 693.27 KB
Scientific paper - Case study
Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
Acta Clinica Belgica, 75 (2020), 5; 357-361. https://doi.org/10.1080/17843286.2019.1608395
Krečak, Ivan; Medić Grgić, Marijana; Gverić–Krečak, Velka; Rončevć, Pavle; Bašić Kinda, Sandra; Babel, Jaksa; Radonić, Radovan

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Krečak, I., Medić Grgić, M., Gverić–Krečak, V., Rončevć, P., Bašić Kinda, S., Babel, J. & Radonić, R. (2020). Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. Acta Clinica Belgica, 75. (5), 357-361. doi: 10.1080/17843286.2019.1608395

Krečak, Ivan, et al. "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab." Acta Clinica Belgica, vol. 75, no. 5, 2020, pp. 357-361. https://doi.org/10.1080/17843286.2019.1608395

Krečak, Ivan, Marijana Medić Grgić, Velka Gverić–Krečak, Pavle Rončevć, Sandra Bašić Kinda, Jaksa Babel and Radovan Radonić. "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab." Acta Clinica Belgica 75, no. 5 (2020): 357-361. https://doi.org/10.1080/17843286.2019.1608395

Krečak, I., et al. (2020) 'Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab', Acta Clinica Belgica, 75(5), pp. 357-361. doi: 10.1080/17843286.2019.1608395

Krečak I, Medić Grgić M, Gverić–Krečak V, Rončevć P, Bašić Kinda S, Babel J, and sur.. Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab. Acta Clinica Belgica [Internet]. 2020 October [cited 2024 December 27];75(5):357-361. doi: 10.1080/17843286.2019.1608395

I. Krečak, et al., "Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab", Acta Clinica Belgica, vol. 75, no. 5, pp. 357-361, October 2020. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:253954. [Accessed: 27 December 2024]

Metadata
Title (english)Coombs-positive refractory acquired thrombotic thrombocytopenic purpura in a patient with chronic myelomonocytic leukemia successfully treated with rituximab
AuthorIvan Krečak
AuthorMarijana Medić Grgić
AuthorVelka Gverić–Krečak
AuthorPavle Rončevć
AuthorSandra Bašić Kinda
AuthorJaksa Babel
AuthorRadovan Radonić
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Acquired thrombotic thrombocytopenic purpura (aTTP) is a rare autoimmune disorder characterized by auto-antibodies to Willebrand factor (vWF) cleaving enzyme (ADAMTS13), resulting in unusually large vWF multimers that lead to platelet aggregation, microthrombi formation and microangiopathic hemolytic anemia. Hemolysis in aTTP is mechanical; thus, direct antiglobulin test (Coombs test) is usually negative. Multiple autoimmune conditions and various auto-antibodies have been described in the context of chronic myelomonocytic leukemia (CMML). In this paper, we describe the first case of CMML with auto-antibodies to ADAMTS13, presenting initially as plasmapheresis-refractory Coombs-positive aTTP. ----- Results: Although our patient was not treated for CMML, a complete remission of aTTP was eventually achieved with rituximab. Conclusion; We propose that aTTP should be in the differential diagnosis of CMML patients with thrombocytopenia and anemia (Coombs positive or not) who develop signs of thrombotic microangiopathy. Further studies are much needed to decipher the immune-mediated processes in CMML.
Keywords (english)
Languageenglish
Publication typeScientific paper - Case study
Publication statusPublished
Peer reviewPeer review
Publication versionAccepted version
Journal titleActa Clinica Belgica
Numberingvol. 75, no. 5, pp. 357-361
p-ISSN1784-3286
e-ISSN2295-3337
DOIhttps://doi.org/10.1080/17843286.2019.1608395
URN:NBNurn:nbn:hr:105:253954
Publication2020-10
Document URLhttps://www.tandfonline.com/doi/full/10.1080/17843286.2019.1608395
Type of resourceText
Access conditionsOpen access
Embargo expiration date: 2021-11-01
Terms of useLicence In copyright icon
Created on2021-01-28 10:22:42